There are multiple factors in making "cold" breast cancer tumors "hot," meaning that they respond to chemotherapy, explained Hope S. Rugo, MD, FASCO, director of Breast Oncology and Clinical Trials Education at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center.
There are multiple factors in making "cold" breast cancer tumors "hot," meaning that they respond to chemotherapy, explained Hope S. Rugo, MD, FASCO, director of Breast Oncology and Clinical Trials Education at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center.
Transcription
We're interested in trying to make cold tumors hot or warm, so getting them to be more immune-reactive, so that the body will actually be able to react to them. You need several factors. You need the tumor to look foreign, you need it not to have so many other features that it overcomes any attempt of the immune system, so you don't want it to be heavily, heavily pre-treated because it's likely to have multiple mechanisms of resistance, although not always. Some people respond late in treatment, just not many.
You want to have an effective immune system. You don't want the host to be so immune-compromised that they can't respond, either. So there are a number of different factors that are at play. Of course the cancer has to be responsive to the chemo drugs you're giving, which is a whole other issue.
Workflow, Educational Tools Improve Use of Silicone Film to Prevent Radiation Dermatitis
April 25th 2024Tools to educate oncology nurses and patients on the use of Mepitel film to prevent radiation dermatitis has improved the workflow around its introduction to patients with breast cancer, as well as its application and maintenance.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.